OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEFERRED ASCT (PADIMAC)
EHA Learning Center, Kwee Yong, 181956
PROPORTION AND COMPOSITION OF BONE MARROW LYMPHOCYTE POOL AT BASELINE CORRELATES WITH OUTCOME IN MM PATIENTS AFTER RVD AND ASCT
EHA Learning Center, Sini Luoma, 181957
VALUE OF THE 18F-FDG PET-CT IN THE IDENTIFYING BONE INVOLVEMENT EITHER AT DIAGNOSIS OR DURING FOLLOW-UP OF PATIENTS AFFECTED BY MULTIPLE MYELOMA.
EHA Learning Center, sara galimberti, 181958
INITIAL PHASE 2 RESULTS OF IBRUTINIB COMBINED WITH BORTEZOMIB/DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA
EHA Learning Center, Roman Hajek, 181959
PROGNOSTIC SIGNIFICANCE OF CLONAL CIRCULATING PLASMA CELLS BY MULTI-PARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
EHA Learning Center, Surbhi Sidana, 181960
RENAL IMPAIRMENT IN MYELOMA - PATIENT CHARACTERISTICS, TREATMENT MODALITIES, STEM CELL TRANSPLANT & OUTCOMES FROM THE AUSTRALIAN AND NEW ZEALAND MYELOMA REGISTRY
EHA Learning Center, Joy Ho, 181961
VENETOCLAX AS TARGETED THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Shaji K Kumar, 181962
AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
EHA Learning Center, Saad Z. Usmani, 181963
GENE EXPRESSION CLASSIFIER EMC92/SKY92 AND REVISED ISS ROBUSTLY IDENTIFY HIGH-RISK MULTIPLE MYELOMA IN ELDERLY PATIENTS OF THE HOVON-87/NMSG-18 STUDY
EHA Learning Center, R Kuiper, 181964
MULTIPLE MYELOMA AND COMORBIDITY: A POPULATION-BASED STUDY
EHA Learning Center, Ingigerdur Solveig Sverrisdottir, 181965
DETECTION OF NEW EMERGING CLONES DURING TREATMENT BY NGS ALLOWS A BETTER RISK PREDICTION ON MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Beatriz Sanchez-Vega, 181966
FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY
EHA Learning Center, Andrzej J. Jakubowiak, 181967
PANOBINOSTAT INDUCES CD38 UPREGULATION AND AUGMENTSTHE ANTI-MYELOMA EFFICACY OF DARATUMUMAB
EHA Learning Center, Estefania Garcia-Guerrero, 181968
BCL2 EXPRESSION IS A POTENTIAL PREDICTIVE BIOMARKER OF RESPONSE TO VENETOCLAX IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Jeremy Ross, 181969
THE IMPACT OF THE INTRODUCTION OF BORTEZOMIB ON DIALYSIS INDEPENDENCE IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE: A NATIONWIDE DUTCH POPULATION-BASED STUDY
EHA Learning Center, Berdien Oortgiesen, 181970
TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND LIGHT CHAIN (AL) AMYLOIDOSIS
EHA Learning Center, Paolo Milani, 181971
MYOCARDIAL UPTAKE OF 99MTC-DPD IN PATIENTS WITH AL AMYLOIDOSIS
EHA Learning Center, Carlos de Miguel Jiménez, 181972
WHEN PERFORMANCE OF CYTOGENETICS MATTERS: A POPULATION-BASED STUDY IN THE NETHERLANDS ON NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Mirian Brink, 181973
AN UPDATED ADJUSTED COMPARISON SUGGESTS DARATUMUMAB IS ASSOCIATED WITH PROLONGED SURVIVAL COMPARED WITH STANDARD OF CARE THERAPIES IN HEAVILY PRE-TREATED AND HIGH REFRACTORY MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Shaji K. Kumar, 181974
PREDICTORS OF EARLY DEATH RELATED TO ACTIVE MULTIPLE MYELOMA IN ELDERLY PATIENTS RECEIVING OPTIMIZED FRONTLINE TREATMENT COMBINATIONS
EHA Learning Center, Paula Rodriguez-Otero, 181975
MPL ACTIVATION DIRECTLY INDUCES FIBROCYTE DIFFERENTIATION TO CAUSE MYELOFIBROSIS
EHA Learning Center, Takaaki Maekawa, 181976
ENGRAFTMENT OF PRIMARY MYELOFIBROSIS BONE MARROW-DERIVED CD14+ MONOCYTES IN NOD-SCID- MICE
EHA Learning Center, Taghi Manshouri, 181977
ESTABLISHMENT OF AN IN VITRO MODEL FOR THE SKEWED MEGAKARYOPOIESIS BY CALRETICULIN MUTATION IN HUMAN CELLS
EHA Learning Center, Hiraku Takei, 181978
QUANTITATIVE PROTEOME HETEROGENEITY IN MYELOPROLIFERATIVE NEOPLASM SUBTYPES AND ASSOCIATION WITH JAK2 MUTATION STATUS
EHA Learning Center, Nuria Socoro Yuste, 181979
THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS
EHA Learning Center, Mathias Schneeweiss, 181980
DISTRIBUTION OF MUTATIONS IN DRIVER AND NON-DRIVER GENES ACCORDING TO CLONAL HEMATOPOIESIS IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA
EHA Learning Center, Alicia Senín, 181981
RUXOLITINIB/NILOTINIB/PREDNISOLONE COMBINATION: A PROMISING NOVEL TREATMENT FOR MYELOFIBROSIS
EHA Learning Center, Joaquin Martinez-Lopez, 181982
INTERLABORATORY ASSESSMENT OF MUTATION DETECTION IN MYELOID MALIGNANCIES BY TARGETED NEXT-GENERATION SEQUENCING
EHA Learning Center, Maria Concepcion Fernandez, 181983
METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE
EHA Learning Center, Suzanne McPherson, 181984
ELUCIDATING THE AGE INDUCED HEMATOPOIETIC CELL-INTRINSIC AND EXTRINSIC MECHANISMS IN MYELOPROLIFERATIVE NEOPLASM INITIATION AND PROGRESSION
EHA Learning Center, Tata Nageswara Rao, 181985
PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL
EHA Learning Center, Moshe Talpaz, 181986
COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS:RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110)
EHA Learning Center, Frank Stegelmann, 181987
PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), IN PATIENTS WITH MYELOFIBROSIS (MF) AND BASELINE (BL) THROMBOCYTOPENIA: FOCUS ON RUXOLITINIB (RUX)-TREATED PATIENTS IN THE PHASE 3 PERSIST-2 TRIAL
EHA Learning Center, Claire Harrison, 181988
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN ELDERLY PATIENTS (≥ 75 YEARS) WITH MYELOFIBROSIS (MF): AN ANALYSIS FROM THE PHASE 3B, EXPANDED-ACCESS JUMP STUDY
EHA Learning Center, Pia Raanani, 181989
PROGNOSTIC RISK MODELS FOR TRANSPLANT DECISION-MAKING IN MYELOFIBROSIS
EHA Learning Center, Juan-Carlos Hernandez-Boluda, 181990
LEUKEMIC TRANSFORMATION AND SECOND CANCERS IN 3649 HIGH RISK ET PATIENTS IN THE EXELS STUDY
EHA Learning Center, Gunnar Birgegard, 181991
EPIDEMIOLOGY, OUTCOME AND RISK FACTORS FOR INFECTIOUS COMPLICATIONS IN MF PATIENTS RECEIVING RUXOLITINIB. A MULTICENTER STUDY ON 373 PATIENTS
EHA Learning Center, Nicola Polverelli, 181992
TREATMENT AND MANAGEMENT OF PATIENTS WITH MPNS—FINDINGS FROM THE INTERNATIONAL MPN LANDMARK SURVEY
EHA Learning Center, Steffen Koschmieder, 181993
SUCCESSFUL LONG-TERM MAINTENANCE OF PV PATIENTS WITH A MONTHLY SCHEDULE OF ROPEGINTERFERON ALFA-2B - AN UPDATE FROM THE PEGINVERA STUDY
EHA Learning Center, Heinz Gisslinger, 181994
NO IMPROVEMENT IN SURVIVAL OVER TIME FOR PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASM PATIENTS WHO TRANSFORM TO ACCELERATED OR BLAST PHASE
EHA Learning Center, Caroline McNamara, 181995
MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY
EHA Learning Center, Olivier Hermine, 181996
THERAPY RESPONSE AND LONG-TERM OUTCOME OF 71 ADULT PATIENTS WITH HEMATOLOGICAL MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SINGLE INSTITUTION EXPERIENCE
EHA Learning Center, Maciej Machaczka, 181997
WHOLE-EXOME SEQUENCING IN CHILDREN WITH IMMUNE CYTOPENIA: THE APPLICABILITY AND CLINICAL IMPACT
EHA Learning Center, Michael Svaton, 181998
SEQUENCING OF THE HYPOXIA PATHWAY GENES IN PATIENTS WITH CONGENITAL ERYTHROCYTOSES BY NEXT GENERATION SEQUENCING
EHA Learning Center, Francois Girodon, 181999
CHARACTERIZATION OF CD34+ HEMATOPOIETIC PRECURSORS IN INDOLENT SYSTEMIC MASTOCYTOSIS AND THEIR POTENTIAL ROLE IN EARLY DISSEMINATION OF THE DISEASE.
EHA Learning Center, Alberto Orfao, 182000
MONOALLELIC VARIANTS IN GENES RELATED TO FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: REPORT FROM THE ITALIAN REGISTRY
EHA Learning Center, Laura vinas, 182001
PRIMARY AND CONGENITAL ERYTHROCYTOSIS IN PEDIATRICS: THE EXPERIENCE OF ITALIAN CENTERS
EHA Learning Center, Giulia Geranio, 182002
NEUROLOGICAL INVOLVEMENT IN EVANS SYNDROME AND CHRONIC HEMOLYTIC AUTOIMMUNE ANEMIA OF CHILDREN: DESCRIPTION, EVOLUTION AND GENETICS
EHA Learning Center, Thomas Pincez, 182003
AUTOIMMUNE NEUTROPENIA OF CHILDHOOD SECONDARY TO OTHER AUTOIMMUNE DISORDERS: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY
EHA Learning Center, Piero Farruggia, 182004
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT DURING PREGNANCY
EHA Learning Center, Maria Vinogradova, 182005
LONG-TERM RESPONSE TO ORAL ELIGLUSTAT IN TREATMENT-NAÏVE ADULTS WITH GAUCHER DISEASE TYPE 1: FINAL EFFICACY AND SAFETY RESULTS FROM A PHASE 2 CLINICAL TRIAL AFTER 8 YEARS OF TREATMENT
EHA Learning Center, Elena Lukina, 182006
REAL WORLD EVIDENCE ON DRUG UTILIZATION PATTERNS OF ELTROMBOPAG IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA: REVIEU (REVOLADE™ [ELTROMBOPAG] IN SELECTED COUNTRIES IN THE EUROPEAN UNION) STUDY
EHA Learning Center, EMILIO OJEDA GUTIERREZ, 182007
BIOLOGICAL CHARACTERIZATION OF ITP PATIENTS THAT ARE NON-RESPONDERS TO TRADITIONAL THERAPIES
EHA Learning Center, Nuria Revilla, 182008
SEQUENTIAL USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ADULT PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE COLLABORATIVE SURVEY FROM ITALIAN HEMATOLOGY CENTERS
EHA Learning Center, Silvia Cantoni, 182009
THROMBOEMBOLIC EVENT MANAGEMENT AND OUTCOMES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ELTROMBOPAG (EPAG): RESULTS FROM THE EXTEND STUDY
EHA Learning Center, Mansoor N Saleh, 182010
ATORVASTATIN IMPROVE THE PROGNOSIS OF ADULT PATIENTS WITH CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA VIA ENHANCING BONE MARROW ENDOTHELIAL CELL FUNCTION
EHA Learning Center, Xie Cao, 182012
PLATELET DESIALYLATION IS A NOVEL MECHANISM AND A THERAPEUTIC TARGET IN THROMBOCYTOPENIA DURING SEPSIS: AN OPEN-LABEL, MULTICENTER, RANDOMIZED CONTROLLED TRIAL
EHA Learning Center, Xin Li, 182013
SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)
EHA Learning Center, James Bussel, 182014
IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF CLL PATIENTS RELAPSED/REFRACTORY TO B-CELL RECEPTOR (BCR) SIGNALING PATHWAY INHIBITOR TREATMENT
EHA Learning Center, William Wierda, 182015
THE ROLE OF PSYCHOLOGICAL VARIABLES FOR TYROSINE KINASE INHIBITORS (TKI) DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: IMPLICATION FOR MEDICAL DECISION MAKING PRACTICE
EHA Learning Center, Alessandra Lurlo and Cristina Buccelli, 182016
BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28 EU MEMBER STATES
EHA Learning Center, Fanni Rencz, 182017
AN INVESTIGATION INTO THE NEEDS AND PRIORITIES OF PATIENTS WITH MULTIPLE MYELOMA DURING REMISSION - IMPLICATIONS FOR RE-DESIGNING PATIENT-CENTRED HEALTHCARE SYSTEMS.
EHA Learning Center, Dunnya DE-SILVA, 182018
COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Matthew Matthew Seftel, 182019
THE THERAPEUTIC UTILITY OF A SYSTEMATIC PROTOCOL FOR GERIATRIC ASSESMENT IN ONCOHEMATOLOGIC PATIENTS
EHA Learning Center, Claudia Milagros Terán Benzaquen, 182020
RADIATION EXPOSURE FROM CT IMAGING AND CHILDHOOD LEUKEMIA: A NATIONWIDE CASE-CONTROL STUDY
EHA Learning Center, Atte Nikkilä, 182021
HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Learning Center, Parameswaran Hari, 182022
MANAGEMENT, ECONOMIC AND SOCIAL IMPACT OF SUB-CUTANEOUS RITUXIMAB ADMINISTRATION IN LYMPHOPROLIFERATIVE MALIGNANCIES
EHA Learning Center, Ombretta Annibali, 182023
EFFECT OF IMPROVEMENTS OF SURVIVAL, POPULATION AGING AND IMWG´14 CRITERIA ON INCIDENCE AND PREVALENCE OF MULTIPLE MYELOMA
EHA Learning Center, Belen Ballina, 182024
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ISOLATED EXTRAMEDULLARY RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN
EHA Learning Center, Maria Gabelli, 182025
PREDICTIVE FACTORS FOR DEVELOPING VENO-OCCLUSIVE DISEASE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Partow Kebriaei, 182026
DEFIBROTIDE EFFICACY AND SAFETY IN PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSED AFTER DAY 21: ANALYSIS OF FINAL DATA FROM AN EXPANDED-ACCESS PROGRAM
EHA Learning Center, Paul Richardson, 182027
ALLO-HCT FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - 12 YEARS OF EXPERIENCE
EHA Learning Center, Miroslaw Markiewicz, 182028
A COMPARISON OF CLINICAL OUTCOMES BETWEEN MATCHED SIBLING DONOR (MSD) AND UNRELATED DONOR (URD) STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA
EHA Learning Center, Seunghwan Shin, 182029
HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANT IN SEVERE THALASSEMIA PATIENTS
EHA Learning Center, Suradej hongeng, 182030
AUGMENTATION OF FLUDARABINE AND BUSULFAN-BASED MYELOABLATIVE REGIMEN WITH THIOTEPA IMPROVES OUTCOMES WITH NO ADDED TOXICITY IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA
EHA Learning Center, Vipul SHETH, 182031
PROGNOSTIC TOOLS CAN PROVIDE PERSONALIZED OUTCOMES PREDICTION AFTER ALLOGENEIC HCT IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
EHA Learning Center, Christina CHO, 182032
THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: IS THERE A PROTECTIVE ROLE FOR URSODEOXYCHOLIC ACID?
EHA Learning Center, Rocio Parody Porras, 182033
FACTORS PREDICTING GRAFT VERSUS HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION. COMPARISON ATTENDING TO TWO DIFFERENT DEFINITIONS AND BENEFICT OF HAPLOIDENTICAL DONOR.
EHA Learning Center, María Dolores Caballero, 182034
EFFICACY AND SAFETY OF DEFIBROTIDE IN THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL SUBGROUP RESULTS
EHA Learning Center, Paul Richardson, 182035
GENERATION OF IMMORTAL MURINE HEMATOPOIETIC STEM/PROGENITOR CELL LINES FROM TRANSGENIC MICE
EHA Learning Center, Eszter Doma, 182036
INHIBITING BCL2 AND NK CELLS IMPROVES STEM CELL TRANSPLANT OUTCOMES.
EHA Learning Center, Joanne Davis, 182037
MESENCHYMAL STROMAL CELL IRRADIATION INTERFERES WITH THE ADIPOGENIC/OSTEOGENIC DIFFERENTIATION BALANCE IMPROVING THEIR HEMATOPOIETIC-SUPPORTING ABILITY
EHA Learning Center, Silvia Preciado Pérez, 182038
DYSFUNCTION OF BONE MARROW MESENCHYMAL STEM CELLS FROM PATIENTS WITH PROLONGED ISOLATED THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN BE IMPROVED BY N-ACETYL-L-CYSTEINE
EHA Learning Center, Yang Song, 182039
INHIBITORS OF APOPTOSIS PROTEINS (IAPS) MODULATE GASTROINTESTINAL GVHD IN MURINE EXPERIMENTAL BMT MODELS
EHA Learning Center, Tomomi Toubai, 182040
GRAFT-VERSUS HOST DISEASE (GVHD) DEVELOPMENT AFTER BONE MARROW TRANSPLANTATION IS NOT INFLUENCED BY TH9 CELLS
EHA Learning Center, Gudrun Strauss, 182041
IMPROVED HSC ENGRAFTMENT IN A MOUSE MODEL OF HEMATOPOIETIC STEM CELL GENE THERAPY MEDIATED BY MSCS
EHA Learning Center, Maria Fernandez-Garcia, 182042
EFFECT OF POMALIDOMIDE ON T CELL POLARIZATION IS MEDIATED THROUGH EPIGENETIC MODIFCATIONS.
EHA Learning Center, Isabel Alvarez Laderas, 182043
MESENCHYMAL STEM CELLS (MSCS) ATTENUATE CUTANEOUS SCLERODERMATOUS GRAFT-VERSUS-HOST DISEASE (SCL-GVHD) THROUGH INHIBITION OF IMMUNE CELL INFILTRATION IN A MOUSE MODEL
EHA Learning Center, Ji-Young Lim, 182044
C57BL/6 SUBTRAINS SHOW DIFFERENCES IN HEMATOPOIETIC REPOPULATION
EHA Learning Center, Antonio Morales Hernandez, 182045
GWAS RESULTS IN RED BLOOD CELL PHENOTYPES AND THEIR RELATIONSHIP WITH THROMBOSIS
EHA Learning Center, Angel F Remacha, 182046
ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS SHOW AN INCREASED THROMBUS FORMATION IN A DYNAMIC MODEL OF PLATELET ADHESION
EHA Learning Center, Alfonso Vignoli, 182047
DOAC ASSOCIATED MAJOR GASTROINTESTINAL BLEEDING: REAL LIFE EXPERIENCE FROM A UNIVERSITY TEACHING HOSPITAL, UK
EHA Learning Center, Buddhika Badugama, 182048
INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING LOWER LIMB SURGICAL REVASCULARIZATION: IS THROMBOPROPHYLAXIS WARRANTED?
EHA Learning Center, Anmol Baranwal, 182050
GENETIC AND ENVIRONMENTAL RELATIONSHIP BETWEEN VITAMIN B12, FOLATE AND HOMOCYSTEINE AND SUSCEPTIBILITY TO THROMBOSIS IN THE GAIT 2 PROJECT. RESULTS OF A GWAS ANALYSIS.
EHA Learning Center, Angel F Remacha, 182052
CELLULAR ORIGIN OF CIRCULATING MICROPARTICLES (MP) ACCORDING TO SOMATIC MUTATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPN)
EHA Learning Center, Alfonso Vignoli, 182053
ARE WE TESTING APPROPRIATELY FOR THE LUPUS ANTICOAGULANT?
EHA Learning Center, Joe Sharif, 182054
RESULTS OF USING BRIDGING THERAPY WITH SODIUM BEMIPARIN AT THERAPEUTIC-DOSE
EHA Learning Center, Almudena Garcia Ruiz, 182055
A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Philippe Moreau, 181747
SAFETY RESULTS OF TERMINATED PHASE 2 STUDY OF IDELALISIB PLUS RITUXIMAB IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH DEL(17P)
EHA Learning Center, Peter Hillmen, 181752
L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY
EHA Learning Center, Maddocks Kami J., 181757